SCHEMBL3935324

SCHEMBL3935324

CCCCCCC(O)[C](C)C

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GPR84 Q9NQS5 7/20 0.62
FFAR1 O14842 2/20 0.62
LMNA P02545 2/20 0.50
SPHK1 Q9NYA1 2/20 0.50
CYP2D6 P10635 2/20 0.46
GMNN O75496 1/20 0.46
POLB P06746 1/20 0.46
THPO P40225 1/20 0.46
MTOR P42345 1/20 0.46
BLM P54132 1/20 0.46
KDM4E B2RXH2 1/20 0.46
TP53 P04637 1/20 0.46
CYP1A2 P05177 1/20 0.46
CYP3A4 P08684 1/20 0.46
MAPT P10636 1/20 0.46
CETP P11597 1/20 0.46
HTT P42858 1/20 0.46
UBE2N P61088 1/20 0.46
FFAR4 Q5NUL3 1/20 0.45
TSHR P16473 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8844301 1.00 GPR84 (0.62) GPR84FFAR1LMNASPHK1CYP2D6
SCHEMBL2019394 1.00 GPR84 (0.62) GPR84FFAR1LMNASPHK1CYP2D6
SCHEMBL3942653 1.00 GPR84 (0.62) GPR84FFAR1LMNASPHK1CYP2D6
SCHEMBL8025685 1.00 GPR84 (0.62) GPR84FFAR1LMNASPHK1CYP2D6
SCHEMBL2549772 1.00 GPR84 (0.62) GPR84FFAR1LMNASPHK1CYP2D6
SCHEMBL8000460 1.00 GPR84 (0.62) GPR84FFAR1LMNASPHK1CYP2D6
SCHEMBL10582525 1.00 GPR84 (0.62) GPR84FFAR1LMNASPHK1CYP2D6
SCHEMBL3946030 0.97 GPR84 (0.58) GPR84FFAR1LMNASPHK1CYP2D6
SCHEMBL3940037 0.88
SCHEMBL16516286 0.85 GPR84 (0.54) GPR84FFAR1LMNASPHK1CYP2D6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-4710491-A N-glycosylated carboxylic acid derivatives as agents for combating rheumatic diseases TROPONWERKE GMBH & CO., KG (DE) 1987-12-01 US claimed
EP-2046147-B1 METHOD OF USING ORGANIC COMPOUNDS GIVAUDAN SA (CH) 2013-05-01 EP disclosed
CN-101084035-B catheter assembly COLOPLAST AS 2010-12-22 CN disclosed
US-20090311403-A1 Method of Using Organic Compounds GIVAUDAN SA (CH) 2009-12-17 US disclosed
EP-2046147-A1 METHOD OF USING ORGANIC COMPOUNDS Givaudan SA (CH) 2009-04-15 EP disclosed
US-7378551-B2 Amide compound KAO CORPORATION (JP) 2008-05-27 US disclosed
WO-2008011742-A1 METHOD OF USING ORGANIC COMPOUNDS GIVAUDAN SA (CH) 2008-01-31 WO disclosed
CN-101084035-A catheter assembly MENTOR CORP (DK) 2007-12-05 CN disclosed
US-20070185208-A1 Amide compound KAO CORPORATION (JP) 2007-08-09 US disclosed
US-5872111-A TOILET BAR SOAP, FACIAL BODY CLEANSER, SHAMPOO, CONDITIONER, COSMETIC,SHAVING CREAM OR LOTION, SHOWER GEL, FABRIC SOFTENING CONDITIONER, AND UNDERARM DEODORANT/ANTI-PERSPIRANT LEVER BROTHERS COMPANY, DIVISION OF CONOPCO, INC. (US) 1999-02-16 US disclosed
CN-1181720-A Remotely programmable matrices with memories and uses thereof IRORI (US) 1998-05-13 CN disclosed
CN-1073467-A Pressure sensitive adhesive composition and use bonding of the pressure sensitive adhesive etc. of said composition LINTEC CORP (JP) 1993-06-23 CN disclosed
EP-0140321-B1 USE OF DERIVATIVES OF AMIDES OF CARBOXYLIC ACIDS IN WHICH THE N ATOM IS SUBSTITUTED BY A GLYCOSYL RADICAL AS GROWTH PROMOTOR IN ANIMAL NUTRITION BAYER AG (DE) 1989-04-12 EP disclosed
US-4710491-A N-glycosylated carboxylic acid derivatives as agents for combating rheumatic diseases TROPONWERKE GMBH & CO., KG (DE) 1987-12-01 US disclosed
US-4683222-A STIMULANTS FOR IMMUNE SYSTEM BAYER AKTIENGESELLSCHAFT (DE) 1987-07-28 US disclosed
US-4680287-A N-glycosylated carboxamide derivatives as growth-promoters in livestock feeding BAYER AKTIENGESELLSCHAFT (DE) 1987-07-14 US disclosed
EP-0091645-B1 DERIVATIVES OF AMIDES OF CARBOXYLIC ACIDS IN WHICH THE N ATOM IS SUBSTITUTED BY A GLYCOSYL RADICAL, METHOD FOR THEIR PREPARATION AND THEIR USE TO INFLUENCE THE IMMUNOGENIC SYSTEM BAYER AG (DE) 1987-02-25 EP disclosed
EP-0147777-A2 Derivatives of M-glycosylated amides of carboxylic acids as a product for combating diseases of the rheumatism type Troponwerke GmbH & Co. KG (DE) 1985-07-10 EP disclosed
EP-0140321-A2 Use of derivatives of amides of carboxylic acids in which the N atom is substituted by a glycosyl radical as growth promotor in animal nutrition BAYER AG (DE) 1985-05-08 EP disclosed
EP-0091645-A1 Derivatives of amides of carboxylic acids in which the N atom is substituted by a glycosyl radical, method for their preparation and their use to influence the immunogenic system BAYER AG (DE) 1983-10-19 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070185208-A1 Amide compound H1-0, H1-2, H1-4 GPR84 154/4885FFAR1 88/4885LMNA 1595/4885
US-20090311403-A1 Method of Using Organic Compounds MGLL, GK, LIPC GPR84 529/4885FFAR1 321/4885LMNA 1235/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.